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HBV-RNA Co-amplification May 
Influence HBV DNA Viral Load 
Determination
Benjamin Maasoumy ,1,2 Anna Maria Geretti,3 André Frontzek,4 Harrison Austin,3 Gudrun Aretzweiler,4  
Monica Garcia-Álvarez,5 Susanne Leuchter,4 Christian O. Simon,6 Ed G. Marins,6 Jesse A. Canchola,6 Markus Cornberg,1,2,7  
Rafael Delgado,5 and Heiner Wedemeyer1,8
Despite effective hepatitis B virus (HBV)-DNA suppression, HBV RNA can circulate in patients receiving nucleoside/ 
nucleotide analogues (NAs). Current assays quantify HBV DNA by either real-time polymerase chain reaction (PCR), 
which uses DNA polymerase, or transcription-mediated amplification, which uses reverse-transcriptase (RT) and RNA 
polymerase. We assessed the effect of RT capability on HBV-DNA quantification in samples from three cohorts, in-
cluding patients with quantified HBV RNA. We compared the HBV-DNA levels by real-time PCR (cobas HBV, 
Roche 6800/8800; Xpert HBV, Cepheid), transcription-mediated amplification (Aptima HBV, Hologic), and real-time 
PCR with added RT capability (cobas HBV+RT). In the first cohort (n  =  45) followed over 192 weeks of NA therapy, 
on-treatment HBV-DNA levels were higher with cobas HBV+RT than cobas HBV (mean difference: 0.14 log10 IU/
mL). In a second cohort (n  =  50) followed over 96 weeks of NA therapy, HBV-DNA viral load was significantly 
higher with the cobas HBV+RT and Aptima HBV compared with the cobas HBV test at all time points after ini-
tiation of NA therapy (mean difference: 0.65-1.16 log10 IU/mL). A clinically significant difference was not detected 
between the assays at baseline. In a third cohort (n  =  53), after a median of 2.2 years of NA therapy, we detected 
HBV RNA (median 5.6 log10 copies/mL) in 23 patients (43.4%). Median HBV-DNA levels by Aptima HBV were 
2.4 versus less than 1 log10 IU/mL in samples with HBV RNA and without HBV RNA, respectively (P  =  0.0006). In 
treated patients with HBV RNA, Aptima HBV measured higher HBV-DNA levels than Xpert HBV and cobas HBV. 
Conclusion: Tests including an RT step may overestimate HBV DNA, particularly in samples with low viral loads as 
a result of NA therapy. This overestimation is likely due to amplification of HBV RNA and may have an impact on 
clinical decisions. (Hepatology Communications 2020;4:983-997).
SEE EDITORIAL ON PAGE 949
Current guidelines for the management of chronic hepatitis B virus (HBV) infection recommend quantitative measurement of cir-
culating HBV DNA to guide therapeutic decisions 
and monitor response to antiviral therapy.(1,2) The 
main endpoint of current treatment strategies is the 
induction of long-term and complete suppression of 
HBV replication.(1) Detection of low, residual HBV-
DNA levels during nucleos(t)ide analogue (NA) 
therapy may have significant clinical consequences, 
including a higher estimated risk of hepatocellular 
Abbreviations: BL, baseline; cccDNA, covalently closed circular DNA; CI, conf idence interval; HBeAG, hepatitis B e surface antigen; HBsAG, 
hepatitis B surface antigen; HBV, hepatitis B virus; HPS, High Pure System; IQR, interquartile range; LL, lower limit; LLOQ, lower limit of 
quantif ication; NA, nucleos(t)ide analogue; OLS, ordinary least squares; PCR, polymerase chain reaction; RT, reverse transcription; TMA, 
transcription-mediated amplif ication; UL, upper limit.
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carcinoma.(3) Repeatedly confirmed undetectable 
(or at least not quantifiable) levels of HBV DNA 
may identify patients in whom NA treatment can 
be discontinued under specific circumstances.(1,4) 
Inaccurate or inconsistent measurement of viral load 
could adversely affect patient care, with some patients 
potentially not receiving the medication they need, 
and others getting antiviral treatment that might no 
longer be required.(1,4) Overestimation of viral load 
may erroneously suggest adherence issues or virologic 
failure, resulting in further inconclusive resistance 
testing and potential changes to treatment that may 
be associated with risk of toxicity, additional cost, and 
emotional distress for the patient.
To date, general agreement has been reported when 
comparing commercial HBV tests across different 
platforms.(5-9) However, in studies comparing HBV 
viral load quantification using analytical performance 
panels, underestimation of values at high viral loads 
and a lack of linearity in performance across the viral 
load range has been reported.(10) Available assays for 
HBV-DNA quantification operate according to one 
of two main designs. Historically, most tests used real-
time polymerase chain reaction (PCR) formats, which 
use different types of DNA polymerases to amplify 
the target DNA. Real-time PCR can also be used to 
quantify RNA; however, this requires the inclusion 
of an extra step of reverse transcription (RT) before 
DNA amplification and RT activity of the poly-
merase. Alternative nucleic acid amplification technol-
ogies recently introduced for HBV include real-time 
transcription-mediated amplification (TMA).(11) Due 
to its excellent sensitivity, TMA has an established 
track record in the context of blood safety(12) and is 
applied to the quantification of human immunodefi-
ciency virus RNA(13) and hepatitis C virus RNA.(14) 
The TMA assay incorporates two enzymes for nucleic 
acid amplification: Moloney murine leukemia virus 
reverse transcriptase and T7 RNA polymerase. This 
makes RT of RNA into DNA potentially part of any 
amplification process.(11) As a result, it appears likely 
that a TMA assay may be prone to amplifying not 
only HBV DNA, but potentially also HBV RNA, 
particularly in those receiving NA therapy.
Following infection, the HBV genome forms a 
covalently closed circular DNA (cccDNA) episome 
in the nucleus of hepatocytes, which functions as the 
viral transcriptional template. The pregenomic HBV 
RNA transcribed from cccDNA must be converted 
into DNA by the viral polymerase to allow produc-
tion of new virus particles for export. By targeting 
the viral polymerase, NAs effectively block produc-
tion of infectious viruses. In patients with high levels 
of cccDNA transcription, excess pregenomic HBV 
RNA can bypass RT (and inhibition by NAs) and be 
exported in HBV-RNA-containing particles, which 
View this article online at wileyonlinelibrary.com.
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are thought to be noninfectious.(15) Thus, patients 
receiving antiviral therapy can have circulating HBV 
RNA despite the NA effectively blocking HBV DNA 
synthesis and virus replication.
To date, the magnitude of any possible overesti-
mation of HBV DNA as a result of amplification of 
HBV RNA, and whether clinically relevant discrep-
ancies need to be taken into consideration, has not 
been investigated. In this study we used samples from 
three independent cohorts to compare HBV-DNA 
measurements obtained by TMA and real-time PCR, 
to explore the impact of adding an RT step to real-
time PCR, and to relate the findings to the duration 
of NA therapy and, in a subset of patients, the direct 
quantification of circulating HBV RNA.
Materials and Methods
stuDy populations
All studies were performed in accordance with 
the International Conference on Harmonization 
Good Clinical Practice Guidelines, the Declaration 
of Helsinki, and relevant local legislation. Ethical 
approval was obtained from the relevant Institutional 
Review Board/Independent Ethics Committee. All 
study cohorts and evaluated HBV-DNA tests are 
summarized in Tables 1 and 2.
Hannover Cohort: HBV Dna 
Quantification by Real-time pCR 
(cobas HBV) and by Real-time pCR 
plus Rt (cobas HBV+Rt)
In a previous study conducted at three sites in 
Germany (Hannover Medical School), Switzerland 
and Korea, we demonstrated the concordance 
between the real-time PCR cobas HBV-DNA assay 
for use on the cobas 6800/8800 Systems (henceforth 
described as cobas HBV) and the real-time PCR 
COBAS TaqMan HBV test for use with the High 
Pure System (HPS; Roche Molecular Diagnostics, 
Pleasanton, CA) (Supporting Fig. S1). The materials 
and methods, as well as the results for this study, have 
been published previously.(8) In an exploratory evalu-
ation, all available samples (n = 191) from 45 patients 
(Supporting Table S1) under NA therapy (principally 
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from the Hannover Medical School (Germany) were 
used to explore the contribution of circulating HBV 
RNA to any viral load difference obtained with the 
standard cobas HBV software and a nonstandard 
total nucleic acid software (cobas HBV+RT), which 
includes an RT step in the PCR profile, allowing for 
the amplification of HBV RNA that otherwise would 
not be amplified at a meaningful level. The need for 
written informed consent was waived by the institu-
tional review board.
DeFine Cohort: HBV Dna 
Quantification by tma (aptima 
HBV), Real-time pCR (cobas HBV), 
and Real-time pCR plus Rt (cobas 
HBV+Rt)
Based on the results of the first study, a second study 
was conducted at two sites in Germany and Spain to 
compare HBV-DNA quantification by cobas HBV, 
cobas HBV+RT, and the TMA Aptima HBV Quant 
assay (henceforth described as Aptima HBV) for 
use with the Hologic Panther system (Hologic Inc., 
Marlborough, MA). A total of 346 plasma samples 
collected from 50 lamivudine-resistant adult patients 
(≥18 years of age) starting salvage therapy with var-
ious NA combinations were collected from baseline 
to week 96 of treatment. Detailed information on the 
design of the DEFINE study and the study popu-
lation has been published elsewhere.(16) Viral load 
concentrations ranged from undetectable to greater 
than 9 log10 IU/mL, overlapping the medical decision 
points (≥20,000, ≥2,000, <2,000, and <50 IU/mL) 
used to direct treatment during the study. All samples 
with enough remaining volume that generated valid 
results for HBV DNA (i.e., n = 271 for both cobas 
HBV and Aptima HBV) were considered for further 
statistical analysis. All samples were anonymized by 
an independent ethics committee–approved proce-
dure. All specimens were derived from archived sam-
ples that had been stored at −20°C or lower for a 
maximum of 10 years (DEFINE trial(16); all patients 
had provided informed consent). Each sample was 
divided into sufficient aliquots to allow at least single- 
replicate testing with each test. HBV-DNA results 
from the original test (cobas HPS) at the time of col-
lection were available for each sample (referred to as 
nominal viral load).
liverpool Cohort: HBV-Dna 
Quantification by tma (aptima HBV) 
and Real-time pCR (Xpert HBV 
and Cobas HBV) in patients With 
Circulating HBV Rna
As part of an ongoing study evaluating HBV-
RNA detection during chronic HBV infection at the 
University of Liverpool, United Kingdom (Research 
Ethics Committee Approval 18/YH/0286, July 
2018), plasma samples from 101 patients underwent 
HBV-RNA quantification by an in-house real-time 
PCR assay that applies the method described by 
van Bömmel et al.(17) and was performed at DDL 
Diagnostic Laboratory (Rijswijk, the Netherlands). 
The assay reported detection/quantification range that 
spans 2.5/4.0-9.5 log10 copies/mL. Aptima HBV is 
the test used for routine care in the accredited National 
Health Service (NHS) diagnostic laboratory of the 
taBle 2. stuDy CoHoRts
Study Cohorts Hannover Cohort DEFINE Cohort Liverpool Cohort
Number of NA-treated patients (n) 45 50 53
Number of retested plasma samples (n) 191 346† 26
Evaluated HBV assays
Without RT cobas HBV (cobas HPS*) cobas HBV (cobas HPS*) cobas HBV
Xpert HBV
With RT cobas HBV+RT cobas HBV+RT Aptima HBV (TMA)
Aptima HBV (TMA)
Specific value for the study Longitudinal follow-up available Longitudinal follow-up available Direct HBV-RNA quantification performed
* Original test that was used before the study. 
†A total of 271 samples with enough remaining volume generated valid results for HBV DNA for both cobas HBV and Aptima HBV.
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Royal Liverpool University Hospital. To determine 
whether there was any overestimation of HBV DNA 
by Aptima HBV, plasma samples from 26 patients 
who had both quantifiable HBV RNA and quanti-
fiable HBV DNA by Aptima HBV were also tested 
for HBV DNA by real-time PCR, using Xpert HBV 
Viral Load (henceforth described as Xpert HBV) 
(Cepheid, Maurens-Scopont, France). Xpert HBV was 
performed in the local diagnostic laboratory, and cobas 
HBV was performed either at a referral NHS labora-
tory or at Roche Diagnostics.
HBV-Dna QuantiFiCation
All tests were performed by trained operators in 
accordance with the manufacturers’ specifications.(18-20) 
Runs were considered valid if both positive and neg-
ative controls were valid and no protocol deviations 
or incidents occurred that might affect the validity of 
the data. If a run was considered invalid, all samples 
included in that run were retested wherever possible. 
The cobas HBV+RT test was performed according to 
an in-house protocol as described previously.
analysis anD statistiCal 
metHoDs
All statistical analyses were carried out using the 
SAS System software version 9.4 through the SAS 
Enterprise Guide software version 7.12 or higher. 
Results were log10-transformed and compared accord-
ing to Clinical and Laboratory Standards Institute 
guidance EP09-A.(21) HBV viral loads were compared 
between assays using the Student t test, and scatter 
plots were overlaid with the Deming regression lines 
used to assess correlation; Bland−Altman plots were 
used to estimate bias. Longitudinal plots were used 
to present viral loads at different time points for indi-
vidual subjects and combined means. For individual 
subject graphs, the viral load trajectory was measured 
using the slope of the regression line for each test. 
When comparing HBV-DNA levels, results below the 
lower limit of quantification (LLOQ) were assigned a 
value of 0.5 × LLOQ (IU/mL) if the assay reported 
qualitative target detection, and a value of 0.0 log10 
IU/mL if the target was not detected. The charac-
teristics of patients with or without detectable HBV 
RNA were compared by chi-square or Fisher’s exact 
test for categorical variables and Kruskal–Wallis test 
for continuous variables.
Results
impaCt oF an Rt step on tHe 
measuRement oF HBV Dna
To investigate the potential impact of an RT step on 
the measurement of HBV DNA, we tested 191 clin-
ical samples taken from 45 patients under treatment 
with NAs for up to 48 months with the cobas HBV 
and cobas HBV+RT tests (Hannover cohort). All 
samples (n = 191) generated valid results (Supporting 
Table S2). Testing these samples with the cobas 
HBV+RT test resulted in a proportionally biased pos-
itive linear correlation, with viral load results that were 
up to 4 log10 IU/mL higher than those detected with 
the standard cobas HBV test (Fig. 1A; mean ± SD, 
0.89 log10 IU/mL ± 1.33; paired Student t test for 
mean difference [min, max] 0.14 log10 IU/mL [−0.70, 
4.25]; P  < 0.0001). Bland−Altman bias analysis con-
firmed these observations (Fig. 1B), with differences 
being particularly evident in samples with low HBV-
DNA levels. A total of 92 of 191 samples tested had 
HBV viral loads less than the LLOQ (detectable or 
undetectable) with the cobas HBV test (Supporting 
Table S2). Of note, 38 (41%) of these samples yielded 
levels at LLOQ or higher when tested with the cobas 
HBV+RT step, with viral loads ranging from 1.06 to 
4.43 log10 IU/mL (Supporting Table S3A).
To confirm these results, we tested samples from 
a second, independent patient cohort. This unique 
cohort consisted of lamivudine-resistant patients start-
ing salvage therapy with entecavir, entecavir + adefo-
vir, or adefovir + lamivudine (DEFINE cohort).(18) A 
total of 346 samples from seven selected time points 
(baseline, and weeks 12, 24, 48, 72, 84, and 96) were 
tested with the cobas HBV and cobas HBV+RT tests. 
Data from all samples that had enough volume and 
generated valid complete paired observations (i.e., 271 
for both cobas HBV and Aptima HBV) were included 
in the analysis. As was the case in the previous anal-
ysis, HBV-DNA levels were consistently higher with 
the cobas HBV+RT test, particularly at lower HBV-
DNA levels (Fig. 2A,B). Fourteen samples had viral 
levels less than the LLOQ with the cobas HBV test. 
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Fig. 1. Comparison of cobas HBV and cobas HBV+RT (Hannover cohort). (A) Deming regression analysis of viral load quantification 
for cobas HBV versus cobas HBV+RT. (B) Bland−Altman bias plot for measurement of HBV with both tests. Abbreviations: BL: 
Baseline; CI, confidence interval; LL, lower limit; OLS, ordinary least squares; UL, upper limit.
Fig. 2. Comparison of cobas HBV and cobas HBV+RT (DEFINE cohort). (A) Deming regression analysis of viral load quantification 
for cobas HBV versus cobas HBV+RT. (B) Bland−Altman bias plot for measurement of HBV with both tests. Of the 346 longitudinal 
observations available from seven selected time points (day 1, weeks 12, 24, 48, 72, 84, and 96), 257 samples with enough remaining volume 
generated valid results for both tests and are included in these plots.
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Of these, five (36%) yielded levels at the LLOQ or 
higher with the cobas HBV+RT test (range: 1.12-3.07 
log10 IU/mL) (Supporting Table S3B).
To further evaluate the impact of RT in tests devel-
oped to quantify HBV-DNA levels, samples from the 
DEFINE cohort were additionally tested with the 
Aptima HBV test, a TMA-based assay that includes an 
RT step. Of the samples available, 253 were within the 
overlapping linear range (1-9 log10 IU/mL) for quanti-
tative HBV DNA for both the cobas HBV and Aptima 
HBV tests. Six samples that generated results less than 
the LLOQ with the cobas HBV test (five undetectable 
and one detectable but less than the LLOQ) gener-
ated results at the LLOQ or higher with the Aptima 
HBV test, with levels ranging from 1.11-2.92 log10 
IU/mL (Supporting Table S3C). Comparison of these 
results similarly indicated a proportionally biased posi-
tive linear correlation among the viral loads quantified 
with each test (Fig. 3A). In line with previous findings, 
Bland−Altman bias analysis showed that the Aptima 
HBV quantified higher HBV-DNA levels than the 
cobas HBV test (relative to the unity line) at the lower 
end of the test range, where HBV DNA is being sup-
pressed by treatment, progressing closer to the unity 
line toward the upper end of the test range (Fig. 3B).
Finally, the two tests incorporating the RT step, 
cobas HBV+RT and Aptima HBV, were compared 
with each other (Fig. 4 and Supporting Table S4) 
and each was compared versus cobas HBV (with-
out RT). Across each of the study time points, the 
differences between the cobas HBV test versus the 
cobas HBV+RT, and the cobas HBV versus Aptima 
HBV, were similar (Table 3). Comparison of samples 
showing quantification of HBV DNA with both the 
cobas HBV+RT and Aptima HBV indicated a near 
1:1 positive linear correlation in HBV-DNA viral 
load (Fig. 4A). Bland−Altman bias analysis further 
revealed minimal alterations between the two differ-
ent tests that include the RT step (Fig. 4B).
longituDinal CompaRison oF 
tests WitH anD WitHout an 
Rt step
As the documented differences between the HBV 
tests with and without the RT step were most prom-
inent in samples with suppressed HBV-DNA levels 
to less than the LLOQ, we decided to investigate the 
impact of NA treatment in more detail. For this pur-
pose, we first compared HBV-DNA results at baseline 
Fig. 3. Comparison of Aptima HBV versus cobas HBV (DEFINE cohort). (A) Deming regression analysis of viral load quantification 
for Aptima HBV versus cobas HBV. (B) Bland−Altman bias plot for measurement of HBV with Aptima and cobas HBV tests. Of the 
346 longitudinal observations available from seven selected time points (day 1, weeks 12, 24, 48, 72, 84, and 96), 271 samples with enough 
remaining volume generated valid results for both tests and are included in these plots.
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and after initiation of salvage therapy in the DEFINE 
cohort (weeks 12, 24, 48, 72, 84, and 96).
Mean viral loads detected by the cobas HBV, cobas 
HBV+RT, and Aptima HBV tests at each time point are 
shown in Fig. 5, along with nominal HBV-DNA levels 
measured by cobas HPS. At baseline, discrepancies 
between the cobas HBV and the two tests that include 
RT were low (mean differences 0.12 and -0.08 log10  
IU/mL for cobas HBV+RT and Aptima HBV, respec-
tively). In contrast, there were significant differences in 
the HBV viral load determined using the assays with 
RT versus no RT after only 12 weeks of NA therapy, 
ranging from 0.65-0.93 log10 IU/mL (P  <  0.0001). 
The difference between Aptima HBV and cobas HBV 
increased from 0.65 log10 IU/mL (P > 0.0001) at week 
12 to a maximum of 1.11 log10 IU/mL (P < 0.0001) at 
week 84 of therapy. The difference between cobas HBV 
and cobas HBV+RT increased from 0.93 log10 IU/mL 
(P  <  0.001) at week 12 to a maximum of 1.16 log10 
IU/mL (P < 0.0001) at treatment week 48. Differences 
between the assays slightly decreased at week 96, yielding 
0.89 log10 IU/mL (P  =  0.0002) and 0.85 log10 IU/mL 
(P  = 0.003) with the cobas HBV and the Aptima HBV, 
and the cobas HBV and the cobas HBV+RT, respectively. 
Of note, no statistically significant difference was docu-
mented between the cobas HBV+RT and the Aptima 
HBV (RT assays) during treatment, with the exception 
of week 12 and 24 (P = 0.02 and P  =  0.0426, respec-
tively). Similarly, no significant differences were observed 
between the cobas HBV and the cobas HPS (no RT 
assays) at weeks 12, 72, 84, and 96 of therapy (Table 3).
A subset of 8 patients had samples available at all 
seven selected time points that were tested across all 
platforms. Descriptive statistics of HBV-DNA lev-
els across these patients for all tests are presented in 
Supporting Table S5, along with the mean and median 
log differences between tests (Supporting Table S6). 
Analyses demonstrated that results were comparable 
for all four tests at baseline and at week 96 (Table 4). 
Results for cobas HBV+RT versus Aptima HBV were 
comparable throughout all time points, and the cobas 
HBV and HPS test results were comparable at all 
time points (apart from week 12; Table 4). However, 
from week 12 until week 84, the Aptima HBV test 
results were significantly different from the cobas HPS 
(mean difference: 0.58-0.99 log10 IU/mL) and cobas 
HBV results (mean difference: 0.94-1.2 log10 IU/mL). 
Similarly, results with cobas HBV were significantly 
different from those with cobas HBV+RT (mean dif-
ference: 1.17-1.42 log10 IU/mL). Longitudinal assess-
ment of the clinical samples throughout the treatment 
of these 8 patients generally corroborated this picture 
Fig. 4. Comparison of Aptima HBV versus cobas HBV+RT (DEFINE cohort). (A) Deming regression analysis of viral load quantification 
for Aptima HBV versus cobas HBV+RT. (B) Bland−Altman bias plot for measurement of HBV with Aptima and cobas HBV+RT tests. 
Of the 346 longitudinal observations available from seven selected time points (day 1, weeks 12, 24, 48, 72, 84, and 96), 258 samples with 
enough remaining volume generated valid results for both tests and are included in these plots.
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(Supporting Fig. S2A-H). Longitudinal assessment of 
samples from all other patients with cobas HBV and 
Aptima HBV is provided in Supporting Fig. S3.
Similar results were documented when comparing 
the cobas HBV and the cobas HBV+RT tests in the 
Hannover cohort. In the overall analyses, differences 
were evident from week 12 until week 192 (end of 
follow-up) (Supporting Fig. S4). Longitudinal data 
for individual patients are presented in Supporting 
Fig. S5.
taBle 3. DiFFeRenCe in HBV-Dna ViRal loaDs (log10 iu/ml): CoBas HBV VeRsus CoBas HBV+Rt 
anD CoBas HBV VeRsus aptima HBV, CoBas Hps VeRsus CoBas HBV anD aptima HBV VeRsus 
HBV+Rt, anD aptima HBV VeRsus CoBas Hps
Week Test Comparison Number of Samples Mean ± SD (log10 IU/mL)
Adjusted*P Value for 
Difference
Baseline cobas HBV+RT vs. cobas HBV 49 0.12 ± 0.15 0.0000
Aptima HBV vs. cobas HBV 49 −0.08 ± 0.26 1.0000
cobas HBV vs. cobas HPS 49 0.12 ± 0.24 0.0205
Aptima HBV vs. cobas HBV+RT 49 −0.20 ± 0.29 0.0005
Aptima HBV vs. cobas HPS 49 0.04 ± 0.29 1.0000
12 cobas HBV+RT vs. cobas HBV 49 0.93 ± 0.53 0.0000
Aptima HBV vs. cobas HBV 49 0.65 ± 0.4 0.0000
cobas HBV vs. cobas HPS 49 −0.17 ± 0.36 0.0519
Aptima HBV vs. cobas HBV+RT 49 −0.29 ± 0.53 0.0151
Aptima HBV vs. cobas HPS 49 0.48 ± 0.38 0.0000
24 cobas HBV+RT vs. cobas HBV 50 1.16 ± 0.64 0.0000
Aptima HBV vs. cobas HBV 50 0.89 ± 0.43 0.0000
cobas HBV vs. cobas HPS 50 −0.22 ± 0.36 0.0027
Aptima HBV vs. cobas HBV+RT 50 −0.27 ± 0.55 0.0426
Aptima HBV vs. cobas HPS 50 0.67 ± 0.39 0.0000
48 cobas HBV+RT vs. cobas HBV 48 1.16 ± 0.72 0.0000
Aptima HBV vs. cobas HBV 48 0.96 ± 0.38 0.0000
cobas HBV vs. cobas HPS 48 −0.28 ± 0.39 0.0003
Aptima HBV vs. cobas HBV+RT 48 −0.20 ± 0.62 0.9520
Aptima HBV vs. cobas HPS 48 0.68 ± 0.4 0.0000
72 cobas HBV+RT vs. cobas HBV 25 0.97 ± 0.68 0.0000
Aptima HBV vs. cobas HBV 25 1.06 ± 0.65 0.0000
cobas HBV vs. cobas HPS 25 −0.26 ± 0.59 1.0000
Aptima HBV vs. cobas HBV+RT 25 0.09 ± 0.63 1.0000
Aptima HBV vs. cobas HPS 25 0.80 ± 0.55 0.0000
84 cobas HBV+RT vs. cobas HBV 15 0.80 ± 0.68 0.0144
Aptima HBV vs. cobas HBV 15 1.11 ± 0.45 0.0000
cobas HBV vs. cobas HPS 15 −0.37 ± 0.59 0.9959
Aptima HBV vs. cobas HBV+RT 15 0.31 ± 0.73 1.0000
Aptima HBV vs. cobas HPS 15 0.74 ± 0.43 0.0004
96 cobas HBV+RT vs. cobas HBV 20 0.85 ± 0.75 0.0026
Aptima HBV vs. cobas HBV 20 0.89 ± 0.64 0.0002
cobas HBV vs. cobas HPS 20 −0.37 ± 0.63 0.5458
Aptima HBV vs. cobas HBV+RT 20 0.04 ± 0.55 1.0000
Aptima HBV vs. cobas HPS 20 0.52 ± 0.65 0.0771
Note: All 256 valid observations with complete paired results are included. Target not detected observations are imputed with a zero value. 
Values below the LLOQ are imputed as 0.5 × LLOQ = 5 IU/mL for cobas HBV, cobas HBV+RT and Aptima HBV, and imputed as 
0.5 × LLOQ = 14.5 IU/mL for the cobas HPS assay. Only complete data within each week across tests are included.
*Adjusted for multiplicity using the Bonferroni method.
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DiFFeRenCe in HBV-Rna leVels 
BetWeen samples WitH anD 
WitHout oVeRestimation oF 
CiRCulating HBV Dna By  
tma-BaseD assays
To further evaluate whether the observed dif-
ferences could be attributed to the amplification 
of HBV RNA, we accessed a third independent 
patient population (Liverpool cohort). In this par-
ticular cohort, HBV RNA was amplified by directly 
applying a specific PCR-based protocol. The cross- 
sectional Liverpool cohort consisted of 101 patients, 
of whom 41 (40.6%) had detectable HBV RNA at 
a median level of 5.6 log10 copies/mL (interquartile 
range (IQR) 2.9-6.8 log10 copies/mL). Patients with 
detectable HBV RNA were more frequently females, 
of Asian ethnicity, hepatitis B e antigen (HBeAg)–
positive, and had higher HBV-DNA levels by Aptima 
HBV than patients without HBV RNA (Table 5). 
Among the 101 patients, there were 53 on antiviral 
treatment and, at the time of sampling, had received 
NA therapy for a median of 2.2 years (IQR 1.1-4.5). 
Of the treated patients, 23 (43.4%) had detectable 
HBV RNA at a median level of 5.6 log10 copies/mL 
(IQR 3.4-6.3 log10 copies/mL), and treatment dura-
tion was slightly shorter in patients with detect-
able HBV RNA relative to those without (Table 5). 
Among treated patients, median HBV-DNA levels 
were 2.4 log10 IU/mL (ranging from <1 to 9.4 log10 
IU/mL) in patients with HBV RNA versus less than 
1 log10 IU/mL (ranging from <1 to 3.5 log10 IU/mL) 
in those without HBV RNA (P = 0.0006). A total of 
26 samples from patients with both detectable HBV 
RNA and quantifiable HBV DNA underwent repeat 
HBV-DNA testing using real-time PCR (Fig. 6). 
Overall, HBV-DNA levels were higher with Aptima 
HBV than Xpert HBV, and the greatest difference 
was seen in patients on antiviral therapy (up to 1.5 
log10 IU/mL). Details of 10 treated patients who 
showed both detectable HBV RNA and quantifiable 
HBV DNA are given in Table 6. After a median of 
1.7 years of antiviral therapy, median HBV-RNA 
levels were 5.9 log10 copies/mL, and median HBV-
DNA levels by Aptima HBV were 3.5 log10 IU/mL. 
HBV-DNA levels were a median of 1.0 log10  
IU/mL higher by Aptima HBV relative to Xpert 
HBV, with similar results obtained with cobas HBV.
A review of medical records indicated that in 3 
of these patients, after continuous NA therapy for 
Fig. 5. Longitudinal assessment of mean on-treatment viral load. Longitudinal plot of mean viral load (across patients) from baseline to 
week 96 of treatment with NAs for cobas HBV, Aptima HBV, cobas HBV+RT, and historical viral load.
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between 2.8 and 4.1 years, persistent quantification 
of HBV DNA by Aptima HBV (the local routine 
test) led to a diagnosis of suboptimal treatment 
responses, increased frequency of follow-up, failed 
attempts at drug-resistance testing by HBV-DNA 
sequencing, unsuccessful treatment intensification 
to dual tenofovir/entecavir therapy, and distress 
for the patients when their adherence to treatment 
was repeatedly questioned. These three cases were 
resolved once testing by real-time PCR demon-
strated effective HBV-DNA suppression; details 
of one of the cases, with results of retrospective 
taBle 4. DiFFeRenCe in HBV-Dna ViRal loaDs (log10 iu/ml): CoBas HBV VeRsus CoBas HBV+Rt 
anD CoBas HBV VeRsus aptima HBV, CoBas Hps VeRsus CoBas HBV anD aptima HBV VeRsus 
HBV+Rt, anD aptima HBV VeRsus CoBas Hps in 8 patients WitH samples aVailaBle at all seVen 
time points aCRoss all HBV tests
Week Test Comparison Number of Samples Mean ± SD (log10 IU/mL) Adjusted*P Value for Difference
Baseline cobas HBV+RT vs. cobas HBV 8 0.15 ± 0.11 0.1928
Aptima HBV vs. cobas HBV 8 0.06 ± 0.22 1.0000
cobas HBV vs. cobas HPS 8 0.02 ± 0.16 1.0000
Aptima HBV vs. cobas HBV+RT 8 −0.09 ± 0.21 1.0000
Aptima HBV vs. cobas HPS 8 0.09 ± 0.12 1.0000
12 cobas HBV+RT vs. cobas HBV 8 1.17 ± 0.44 0.0050
Aptima HBV vs. cobas HBV 8 0.94 ± 0.33 0.0033
cobas HBV vs. cobas HPS 8 −0.36 ± 0.19 0.0413
Aptima HBV vs. cobas HBV+RT 8 −0.24 ± 0.51 1.0000
Aptima HBV vs. cobas HPS 8 0.58 ± 0.26 0.0153
24 cobas HBV+RT vs. cobas HBV 8 1.41 ± 0.46 0.0019
Aptima HBV vs. cobas HBV 8 1.19 ± 0.3 0.0003
cobas HBV vs. cobas HPS 8 −0.37 ± 0.25 0.1444
Aptima HBV vs. cobas HBV+RT 8 −0.21 ± 0.58 1.0000
Aptima HBV vs. cobas HPS 8 0.82 ± 0.19 0.0002
48 cobas HBV+RT vs. cobas HBV 8 1.42 ± 0.57 0.0075
Aptima HBV vs. cobas HBV 8 1.2 ± 0.31 0.0004
cobas HBV vs. cobas HPS 8 −0.38 ± 0.25 0.1329
Aptima HBV vs. cobas HBV+RT 8 −0.21 ± 0.65 1.0000
Aptima HBV vs. cobas HPS 8 0.82 ± 0.25 0.0011
72 cobas HBV+RT vs. cobas HBV 8 1.23 ± 0.52 0.0099
Aptima HBV vs. cobas HBV 8 1.08 ± 0.63 0.0638
cobas HBV vs. cobas HPS 8 −0.1 ± 0.61 1.0000
Aptima HBV vs. cobas HBV+RT 8 −0.16 ± 0.75 1.0000
Aptima HBV vs. cobas HPS 8 0.97 ± 0.35 0.0038
84 cobas HBV+RT vs. cobas HBV 8 1.17 ± 0.59 0.0289
Aptima HBV vs. cobas HBV 8 1.07 ± 0.51 0.0194
cobas HBV vs. cobas HPS 8 −0.08 ± 0.51 1.0000
Aptima HBV vs. cobas HBV+RT 8 −0.1 ± 0.68 1.0000
Aptima HBV vs. cobas HPS 8 0.99 ± 0.2 0.0001
96 cobas HBV+RT vs. cobas HBV 8 1.14 ± 0.83 0.2133
Aptima HBV vs. cobas HBV 8 0.98 ± 0.8 0.3558
cobas HBV vs. cobas HPS 8 −0.17 ± 0.71 1.0000
Aptima HBV vs. cobas HBV+RT 8 −0.16 ± 0.67 1.0000
Aptima HBV vs. cobas HPS 8 0.81 ± 0.53 0.1188
Note: All 256 valid observations with complete paired results across all seven selected time points, across all assays, are included. Target 
not detected observations are imputed with a zero value. Values below the LLOQ are imputed as 0.5 × LLOQ = 5 IU/mL for cobas HBV, 
cobas HBV+RT and Aptima HBV, and imputed as 0.5 × LLOQ = 14.5 IU/mL for the cobas HPS assay. Only complete data within each 
week across tests are included.
*Adjusted for multiplicity using the Bonferroni method.
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HBV-DNA testing by cobas HBV and cobas 
HBV+RT, are shown in Supporting Fig. S6.
Discussion
Accurate quantification of HBV-DNA levels 
guides the clinical management of chronic HBV 
infection.(1,2) We investigated HBV-DNA quantifi-
cation in three independent cohorts of patients with 
the specific aim of assessing how inclusion of RT 
capability in a viral load assay influenced the results. 
The key finding was that tests with an RT step 
(cobas HBV+RT and Aptima HBV) differed in their 
quantification of HBV DNA for patients undergoing 
treatment with NAs compared to tests without an 




P ValueYes (n = 41) No (n = 60)
Age, median years (IQR) 36 (29, 43) 37 (30, 42) 36 (29, 44) 0.9948
Female, n (%) 40 (39.6) 22 (55.0) 18 (45.0) 0.0228*
Male, n (%) 61 (60.4) 19 (31.1) 42 (68.9) —
Ethnicity, n (%)
Asian 53 (52.5) 29 (54.7) 24 (45.3) 0.0042†
Black African 32 (31.7) 6 (18.8) 26 (81.2) —
White 16 (15.8) 6 (37.5) 10 (62.5) —
HBeAg, n (%)
Negative 76 (75.2) 22 (28.9) 54 (71.1) <0.0001‡
Positive 25 (24.8) 19 (76.0) 6 (24.0) —
On antiviral therapy, n (%) 53 (52.5) 23 (43.4) 30 (56.6) 0.1713§
Duration of therapy, median years (IQR)|| 2.2 (1.1, 4.5) 1.3 (0.8, 3.5) 3.9 (1.6, 6.8) 0.0494




§On antiviral therapy versus untreated.
||Among treated patients.
Fig. 6. Difference in HBV-DNA levels quantified by TMA (Aptima HBV) and real-time PCR (Xpert HBV). Each dot indicates 
a single patient (n = 26). The solid dots indicate patients who were receiving antiviral therapy at the time of sampling (n = 10), whose 
characteristics are detailed in Table 6.
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RT step (cobas HBV, cobas HPS, and Xpert HBV). 
Although the cobas HBV+RT and Aptima HBV 
tests demonstrated good agreement with tests with-
out the RT step at baseline, they appeared to consis-
tently overestimate HBV-DNA viral load in samples 
collected during NA therapy, specifically when HBV 
DNA is declining or even completely suppressed. 
Our data indicate that the difference is dependent on 
both the persistence of circulating HBV RNA during 
treatment and the decreasing HBV-DNA to HBV-
RNA ratio. Subsequently, HBV-DNA levels were 
fully or almost fully suppressed by real-time PCR but 
quantifiable by Aptima HBV in some patients.
HBV tests operate using different designs. Tests 
such as cobas HBV or Xpert HBV use real-time 
PCR amplification,(18,20) whereas tests such as 
Aptima HBV use TMA.(19) TMA is not a DNA-
specific detection tool, as it includes intrinsic RT 
capability that can amplify HBV RNA once the tar-
get is detected, a process that creates RNA and DNA 
fragments.(11) Most previous studies comparing 
labeled HBV-DNA tests on different platforms have 
found overall correlation between the viral loads.(5-
9) However, an overestimation with the Aptima 
HBV test later in NA treatment compared with the 
cobas HPS test has been previously reported, but 
the authors suggested that further analysis into the 
samples would be needed to understand the effect.(6) 
Our data indicate that presence of circulating HBV 
RNA in a subset of NA-treated patients is likely to 
be responsible for these reported discrepancies. It 
should be noted that the cobas HBV assay uses a 
DNA polymerase also capable of RT. Although this 
may theoretically also allow amplification of RNA in 
the standard setup of the cobas assay, estimated levels 
of HBV DNA were far higher by cobas HBV+RT 
and Aptima HBV. However, HBV-DNA levels mea-
sured by cobas HBV were not different from those 
measured by Xpert HBV or by cobas HPS, which 
was used widely to determine the currently recom-
mended HBV-DNA thresholds for the initiation and 
monitoring of NA therapy. Thus, we conclude that a 
theoretically low-level quantification of HBV RNA 
by cobas HBV would not be of clinical significance.
In our longitudinal evaluations, the difference 
in HBV-DNA levels measured by assays with and 
without RT capability became clearly evident after 
the start of NA therapy, persisting in consecu-
tive samples collected over long-term follow-up. 
In comparison with the marked effect of NA 
therapy on levels of HBV DNA, its influence on 
HBV RNA is limited. Differences in viral kinet-
ics between HBV DNA and HBV RNA have been 
reported previously, with serum HBV RNA being 
reported as pregenomic RNA in virus-like parti-
cles.(17,22) At baseline, HBV-RNA levels have been 
described to be 1.2 to 2.2 log10 IU/mL lower than 
HBV DNA.(17) This may explain why all tests eval-
uated quantified HBV-DNA levels comparably at 
baseline. However, NA treatment inhibits the viral 
polymerase preventing the formation of HBV DNA 
from the pregenomic HBV-RNA template already 
encapsidated, which can be enveloped and then 
secreted in plasma as virus-like particles that are 
taBle 6. CHaRaCteRistiCs oF patients on antiViRal tHeRapy anD BotH DeteCtaBle HBV Rna 
anD QuantiFiaBle HBV Dna By aptima HBV, RanKeD By DuRation oF tReatment
Subject Country of Origin Age HBeAg NA
Duration of Therapy 
(Years)
HBV RNA log10 
Copies/mL
HBV DNA (log10 IU/mL)
Aptima Xpert Cobas
M1 Vietnam 24 + TDF 0.1 4.3 5.0 3.5 3.5
M2 China 56 + TDF 0.2 4.7 3.9 2.8 2.7
M3 Zambia 26 + TDF 0.3 8.6 9.4 9.5 9.6
F1 United Kingdom 22 + ETV 0.9 7.6 4.3 3.4 3.5
M4 United Kingdom 24 + TDF 1.1 7.4 3.4 3.0 Not done
F2 China 29 + ETV 2.3 7.0 3.5 3.2 3.3
M5 China 37 + TDF 2.8 6.0 2.3 <LLOQ <LLOQ
M6 China 38 + TDF 3.1 5.6 2.6 2.0 2.1
F3 China 35 + TDF 4.1 5.8 1.9 <LLOQ <LLOQ
F4 China 33 + TDF 4.1 4.8 2.4 <LLOQ <LLOQ
Abbreviations: ETV, entecavir; F, female; M, male; TDF, tenofovir disoproxil fumarate.
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resistant to plasma RNAse.(17,23) Consequently, the 
balance becomes shifted toward RNA-containing 
particles, which become predominant as DNA lev-
els decline over time. As a result, relatively higher 
HBV-RNA levels are likely leading to the enhanced 
difference between HBV tests with and without an 
RT step during NA therapy, as documented in our 
study. This is clinically important, as medical deci-
sions during NA therapy are based on HBV-DNA 
levels.(1,2,4) Changes in viral load of 1 log10 IU/mL 
are used to define different levels of response or 
virologic breakthrough, depending on the treatment 
guidelines. Therefore, overestimations greater than 
1 log10 IU/mL may lead to the misclassification of 
a patient and have a meaningful impact on their 
treatment. Undetectable, or at least not quantifiable, 
HBV DNA is considered as the definition of com-
plete response to NA treatment, and the detection 
of HBV-RNA particles influencing the reported 
result can lead to an HBV-DNA-suppressed patient 
being classified as failing therapy, as it was the case 
in at least 3 patients of the Liverpool cohort.
Circulating HBV RNA has recently been sug-
gested as a potential surrogate of transcriptionally 
active hepatic cccDNA.(15,24,25) Although HBV-
DNA suppression through treatment with NAs is the 
main endpoint, undetectable HBV DNA does not 
indicate suppressed cccDNA activity.(17) Although 
hepatitis B surface antigen (HBsAg) levels correlate 
better with cccDNA levels in this population, some 
of the HBsAgs present in plasma could originate 
from integrated HBV DNA(24,25); this makes HBsAg 
an unreliable surrogate for cccDNA. A more reliable 
surrogate could be HBV RNA. The difference in 
HBV RNA decline relative to HBV DNA suggests 
that cccDNA activity persists and is of interest for 
the development of new therapies that target clini-
cal cure in chronic hepatitis B. Monitoring of HBV 
RNA could be useful in the assessment of treatment 
response to therapies, such as core protein allosteric 
modulators, with the potential to predict sustained 
response that would be classified as clinical cure 
when monitoring response from therapies targeting 
the cccDNA or other steps in the viral life cycle.(17) 
To achieve this, an ability to distinguish between 
DNA and RNA would be critical, and most recently, 
undetectable HBV RNA has been suggested as an 
indicator of safe cessation of currently available NA 
therapy.(26) The evaluation of tests with an RT step, 
as well as the direct detection in a subset of patients 
(Liverpool cohort), afforded us the opportunity to 
investigate HBV-RNA kinetics during NA therapy 
in more detail. It is clear from our study that HBV 
RNA persists in many patients and is likely to be 
detectable for several months during treatment. Data 
from the Hannover cohort support the persistence 
of HBV RNA in HBV-DNA-suppressed patients 
being treated with the most potent regimens (ente-
cavir or tenofovir disoproxil fumarate) for up to 
196 weeks. This is in line with recently published 
data reporting detectable HBV RNA in 30% and 
14% of patients after 3 and 5 years of NA therapy, 
respectively.(26) However, longitudinal data from our 
patients indicate two patterns of HBV-RNA kinet-
ics: one in which HBV RNA persists despite treat-
ment with NAs, and another in which HBV RNA 
declines with HBV DNA. This observation indi-
cates the need for further studies.
Our study has several limitations. In the current 
study, the results generated with the cobas 6800 and 
Panther platforms were compared with historical 
results that were used for medical decision making, 
and therefore considered the benchmark; this was due 
to there not being enough volume to retest samples 
in parallel with the reference method used in these 
original studies. Although samples across the HBV 
genotypes were assessed, it was beyond the scope of 
this analysis to determine whether any of the effects 
were genotype-specific. In addition, the conduct of 
the exploratory analysis with the Hannover cohort 
samples predates the availability of the Aptima HBV 
test; as such, analysis of these samples with this test 
was not possible.
Comparison of HBV-DNA tests in this study sug-
gests that HBV-DNA levels are consistently overes-
timated, on average, with those tests that incorporate 
an RT step throughout the first 96 weeks of therapy, 
as HBV RNA and HBV DNA can be amplified. Of 
note, this affects widely used tests that are based on 
TMA. The overestimation of viral load due to the 
interference of HBV RNA may lead to the misclas-
sification of treatment responses with subsequent 
unnecessary clinical interventions.
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